

Francesco Marongiu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1089911/publications.pdf>

Version: 2024-02-01

127
papers

3,668
citations

201385

27
h-index

138251

58
g-index

127
all docs

127
docs citations

127
times ranked

3406
citing authors

#	ARTICLE	IF	CITATIONS
1	Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. <i>Blood</i> , 2018, 132, 1365-1371.	0.6	573
2	Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 237-242.	1.9	527
3	Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. <i>Blood</i> , 2011, 118, 4714-4718.	0.6	404
4	Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation.. <i>Thrombosis and Haemostasis</i> , 2011, 106, 868-876.	1.8	158
5	Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. <i>Blood</i> , 2010, 115, 481-488.	0.6	134
6	Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2003, 32, 285-295.	1.6	133
7	Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 925-930.	1.9	95
8	Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience. <i>Frontiers in Immunology</i> , 2020, 11, 605688.	2.2	92
9	Uneven hepatic iron and phosphorus distribution in beta-thalassemia. <i>Journal of Hepatology</i> , 1995, 23, 544-549.	1.8	91
10	Pulmonary thrombosis in 2019-CoV pneumonia?. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1511-1513.	1.9	75
11	Warfarin or Acenocoumarol: Which Is better in the Management of Oral Anticoagulants?. <i>Thrombosis and Haemostasis</i> , 1998, 80, 899-902.	1.8	65
12	Patient education and oral anticoagulant therapy. <i>Haematologica</i> , 2002, 87, 1081-6.	1.7	52
13	The Management of Oral Anticoagulant Therapy: The Patient's Point of View. <i>Thrombosis and Haemostasis</i> , 2000, 83, 49-53.	1.8	50
14	The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation. <i>PLoS ONE</i> , 2015, 10, e0124719.	1.1	50
15	Anticardiolipin antibodies in Grave's disease: Relationship with thrombin activity in vivo. <i>Thrombosis Research</i> , 1991, 64, 745-749.	0.8	43
16	A Comparison of Lupus Anticoagulant-Positive Patients With Clinical Picture of Antiphospholipid Syndrome and Those Without. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, e309-10.	1.1	43
17	Thyroid, hemostasis and thrombosis. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 1065-1071.	1.8	42
18	Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 531-535.	1.9	40

#	ARTICLE	IF	CITATIONS
19	Fibrinogen and fibrinolytic activity in hyperthyroidism before and after antithyroid treatment. <i>Journal of Endocrinological Investigation</i> , 1988, 11, 723-725.	1.8	36
20	Pulmonary Thrombosis: A Clinical Pathological Entity Distinct from Pulmonary Embolism?. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 778-783.	1.5	36
21	Point-of-care testing INR: an overview. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 800-805.	1.4	35
22	Abnormalities of Blood Coagulation and Fibrinolysis in Psoriasis. <i>Dermatology</i> , 1994, 189, 32-37.	0.9	34
23	±2antiplasmin and disseminated intravascular coagulation in liver cirrhosis. <i>Thrombosis Research</i> , 1985, 37, 287-294.	0.8	32
24	Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA). <i>Thrombosis Research</i> , 2010, 126, 150-153.	0.8	30
25	Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago. <i>Internal and Emergency Medicine</i> , 2017, 12, 1109-1119.	1.0	30
26	Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1979-1987.	1.9	29
27	Activation of Blood Coagulation and Fibrinolysis in Graves' Disease. <i>Hormone and Metabolic Research</i> , 1991, 23, 609-611.	0.7	28
28	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. <i>American Journal of Hematology</i> , 2009, 84, 579-583.	2.0	28
29	The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures. <i>Internal and Emergency Medicine</i> , 2018, 13, 1029-1036.	1.0	27
30	Acute and chronic hepatitis delta virus infection: Direct or indirect effect on hepatitis B virus replication?. <i>Journal of Medical Virology</i> , 1988, 26, 279-288.	2.5	22
31	Point-of-care (POCT) prothrombin time monitors: is a periodical control of their performance useful?. <i>Thrombosis Research</i> , 2009, 123, 775-779.	0.8	22
32	Optimizing DIEP Flap Insetting for Immediate Unilateral Breast Reconstruction: A Prospective Cohort Study of Patient-Reported Aesthetic Outcomes. <i>Plastic and Reconstructive Surgery</i> , 2019, 143, 261e-270e.	0.7	22
33	Warfarin or acenocoumarol: which is better in the management of oral anticoagulants?. <i>Thrombosis and Haemostasis</i> , 1998, 80, 899-902.	1.8	22
34	Is the imbalance between thrombin and plasmin activity in diabetes related to the behaviour of antiplasmin activity?. <i>Thrombosis Research</i> , 1990, 58, 91-99.	0.8	19
35	Contralateral breast symmetrisation in unilateral DIEP flap breast reconstruction. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2016, 69, 1363-1373.	0.5	19
36	A New Human-Derived Acellular Dermal Matrix for Breast Reconstruction Available for the European Market: Preliminary Results. <i>Aesthetic Plastic Surgery</i> , 2018, 42, 434-441.	0.5	19

#	ARTICLE	IF	CITATIONS
37	Is a Hypercoagulable State Present in Hypothyroidism?. <i>Thrombosis and Haemostasis</i> , 1992, 67, 729-729.	1.8	18
38	The management of oral anticoagulant therapy: the patient's point of view. <i>Thrombosis and Haemostasis</i> , 2000, 83, 49-53.	1.8	18
39	Bleeding diathesis and gastro-duodenal ulcers in inherited cytosolic phospholipase-A2 alpha deficiency. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1182-1189.	1.8	17
40	Rheumatoid arthritis and thrombosis. <i>Clinical and Experimental Rheumatology</i> , 2009, 27, 846-55.	0.4	17
41	Telemedicine can improve the quality of oral anticoagulation using portable devices and self-testing at home. <i>Journal of Telemedicine and Telecare</i> , 2013, 19, 298-301.	1.4	16
42	Center-Related Determinants of VKA Anticoagulation Quality: A Prospective, Multicenter Evaluation. <i>PLoS ONE</i> , 2015, 10, e0144314.	1.1	16
43	A retrospective cohort study of patients with pulmonary embolism: the impact of comorbidities on patient's outcome. <i>European Respiratory Journal</i> , 2016, 48, 555-557.	3.1	15
44	Clot wave analysis and thromboembolic score in liver cirrhosis: two opposing phenomena. <i>International Journal of Laboratory Hematology</i> , 2017, 39, 369-374.	0.7	14
45	Are prothrombin time and clot waveform analysis useful in detecting a bleeding risk in liver cirrhosis?. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 118-123.	0.7	14
46	The venous thromboembolic risk and the clot wave analysis: a useful relationship?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 448-453.	1.4	13
47	Prophylaxis of peripartum haemorrhage using recombinant factor VIIa (rFVIIa) in pregnant women with congenital factor VII deficiency: A case report and literature review. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2019, 235, 77-80.	0.5	13
48	A "two-step" educational approach for patients taking oral anticoagulants does not improve therapy control. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 22, 185-190.	1.0	12
49	The criteria of the Italian Federation of Thrombosis Centres on DOACs: a "real world" application in nonvalvular atrial fibrillation patients already on Vitamin K Antagonist. <i>Internal and Emergency Medicine</i> , 2015, 10, 157-163.	1.0	12
50	Portable coagulometer for vitamin K-antagonist monitoring: the patients' point of view. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 1521-1526.	0.8	12
51	A New Human-Derived Acellular Dermal Matrix for 1-Stage Coverage of Exposed Tendons in the Foot. <i>International Journal of Lower Extremity Wounds</i> , 2020, 19, 78-85.	0.6	12
52	Sub-muscular Reconstruction after NAC Sparing Mastectomy: Direct to Implant Breast Reconstruction with Human ADM Versus Tissue Expander. <i>Aesthetic Plastic Surgery</i> , 2021, 45, 413-420.	0.5	12
53	Changes in fibrinolysis in patients with localized tumors. <i>European Journal of Cancer & Clinical Oncology</i> , 1990, 26, 83-87.	0.9	11
54	Known vitamin K intake and management of poorly controlled oral anticoagulant therapy. <i>Lancet</i> , The, 1992, 340, 545-546.	6.3	11

#	ARTICLE	IF	CITATIONS
55	Apathetic Graves' disease and acquired hemophilia due to factor VIIIc antibody. <i>Journal of Endocrinological Investigation</i> , 2002, 25, 246-249.	1.8	11
56	Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190BCR-ABL oncoprotein and JAK2V617F mutation. <i>Leukemia Research</i> , 2010, 34, e27-e29.	0.4	11
57	Antiphospholipid syndrome patients: The performance of Coagucheck XS in the monitoring of Vitamin K-Antagonists. <i>Thrombosis Research</i> , 2012, 129, e168-e170.	0.8	11
58	Thyroid Disorders and Hypocoagulability. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 011-016.	1.5	10
59	Patients' adherence to oral anticoagulants therapy: Comparison between vitamin K antagonists and direct oral anticoagulants. <i>International Journal of Cardiology</i> , 2021, 333, 162-166.	0.8	10
60	Hemarthrosis as acute presentation of acquired hemophilia in a patient with systemic lupus erythematosus: successful treatment and long-lasting remission. <i>Clinical Rheumatology</i> , 2008, 27, 1581-1584.	1.0	9
61	Vaping effects on asthma: results from a web survey and clinical investigation. <i>Internal and Emergency Medicine</i> , 2020, 15, 663-671.	1.0	9
62	The future of anticoagulation clinics: a journey to thrombosis centers?. <i>Haematologica</i> , 2005, 90, 298.	1.7	9
63	Thrombocytopenia and liver cirrhosis evidence for relationship between platelet count, spleen size and hepatic synthetic activity. <i>Thrombosis Research</i> , 1987, 45, 275-278.	0.8	8
64	Contralateral DIEV as an interpositional vein graft for venous supercharge in the salvage of a congested DIEP flap. <i>Microsurgery</i> , 2016, 36, 263-264.	0.6	8
65	A "Catastrophic" Heparin-Induced Thrombocytopenia. <i>Case Reports in Medicine</i> , 2020, 2020, 1-3.	0.3	8
66	Role of circulating endothelial cells in assessing the severity of systemic sclerosis and predicting its clinical worsening. <i>Scientific Reports</i> , 2021, 11, 2681.	1.6	8
67	High frequency of inadequate test requests for antiphospholipid antibodies in daily clinical practice. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 695-698.	1.4	7
68	Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment. <i>International Journal of Hematology</i> , 2017, 105, 532-535.	0.7	7
69	Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs. <i>European Journal of Internal Medicine</i> , 2020, 80, 73-77.	1.0	7
70	Comparison between Recombinant and Rabbit Thromboplastin in the Management of Patients on Oral Anticoagulant Therapy. <i>Thrombosis and Haemostasis</i> , 1996, 75, 488-490.	1.8	7
71	Risk of reoperation in bioprosthetic valve patients with indication for long-term anticoagulation. Results from the observational retrospective multicentre PLECTRUM study. <i>Open Heart</i> , 2018, 5, e000837.	0.9	6
72	Position paper on the safety/efficacy profile of Direct Oral Anticoagulants in patients with Chronic Kidney Disease: Consensus document of Società Italiana di Nefrologia (SIN), Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA) and Società Italiana per lo Studio dell'Emostasi e della Trombosi (SISSET). <i>Journal of Nephrology</i> , 2021, 34, 31-38.	0.9	6

#	ARTICLE	IF	CITATIONS
73	“Bifidus pedicle”, The Use of Bilobed Superomedial Pedicle for Breast Reshaping Following Upper Outer Quadrantectomy: A New Oncoplastic Breast Surgery Technique. <i>Aesthetic Plastic Surgery</i> , 2021, 45, 866-874.	0.5	6
74	Prothrombin Fragment F 1+2 Levels are High in NIDDM Patients Independently of the Hb A1 c. <i>Thrombosis and Haemostasis</i> , 1995, 74, 805-806.	1.8	6
75	T lymphocyte subsets and viral infections in sardinian parenteral drug abusers: Relationship to HIV infection. <i>Journal of Medical Virology</i> , 1989, 27, 81-86.	2.5	5
76	Bleeding time is prolonged during oral anticoagulant therapy. <i>Thrombosis Research</i> , 1990, 59, 905-912.	0.8	5
77	Special indications for vitamin K antagonists: a review. <i>Internal and Emergency Medicine</i> , 2012, 7, 21-25.	1.0	5
78	Thrombosis centres and AVKs monitoring in COVID-19 pandemic. <i>Internal and Emergency Medicine</i> , 2020, 15, 1365-1368.	1.0	5
79	The Repeatable Battery for the Assessment of Neuropsychological Status as a screening strategy for HIV-Associated Neurocognitive Disorders. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 357-363.	0.6	5
80	Infectious agents including COVID-19 and the involvement of blood coagulation and fibrinolysis. A narrative review. <i>European Review for Medical and Pharmacological Sciences</i> , 2021, 25, 3886-3897.	0.5	5
81	Thrombin Activity and Oral Anticoagulant Therapy: A Preliminary Study. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1989, 19, 142-146.	0.5	4
82	Fondaparinux: Should It Be Studied in Patients with COVID-19 Disease?. <i>TH Open</i> , 2020, 04, e300-e302.	0.7	4
83	The Behaviour of Protein C in Diabetes Is still an Open Question. <i>Thrombosis and Haemostasis</i> , 1991, 66, 267-267.	1.8	4
84	Thromboembolic disease in patients with rheumatoid arthritis undergoing joint arthroplasty: Update on prophylaxes. <i>World Journal of Orthopedics</i> , 2014, 5, 645.	0.8	4
85	Thrombin Activity and Oral Anticoagulant Therapy: A Further Evaluation. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1990, 20, 63-64.	0.5	3
86	Inhibition of blood coagulation activation and oral anticoagulants in patients with mechanical heart valve prostheses. <i>Thrombosis Research</i> , 1996, 81, 403-406.	0.8	3
87	Dermatan Sulphate, Heparin Cofactor II, and F1+2 Peptide in Non-Insulin-Dependent Diabetes Mellitus. <i>Thrombosis Research</i> , 2000, 97, 263-265.	0.8	3
88	Oral anticoagulant therapy: should doctors change the way they give patients explanations ?. <i>Thrombosis and Haemostasis</i> , 2003, 90, 159-160.	1.8	3
89	Vitamin K Antagonists (Coumarins), Drugs Used in the Prevention and Treatment of Cardioembolism, Deep Vein Thrombosis, and Pulmonary Embolism. , 2015, , 395-398.		3
90	Direct oral anticoagulants: what can we learn?. <i>Internal and Emergency Medicine</i> , 2018, 13, 989-992.	1.0	3

#	ARTICLE	IF	CITATIONS
91	Oral anticoagulant therapy and telemedicine. Internal and Emergency Medicine, 2006, 1, 166-167.	1.0	2
92	Direct inhibitors of thrombin and factor Xa: the importance of laboratory skills. Internal and Emergency Medicine, 2014, 9, 897-898.	1.0	2
93	Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? No. Internal and Emergency Medicine, 2018, 13, 1015-1018.	1.0	2
94	Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA_2DS_2-VASc 1 or 2): A treatment dilemma. Cardiovascular Therapeutics, 2018, 36, e12310.	1.1	2
95	Olanzapine-Associated Portal and Superior Mesenteric Vein Thrombosis. American Journal of Therapeutics, 2020, 27, e419-e420.	0.5	2
96	Invited Response on: Comment on "The First use of Human-Derived ADM in Prepectoral Direct-to-Implant Breast Reconstruction after Skin Reducing Mastectomy." Aesthetic Plastic Surgery, 2021, 45, 1934-1935.	0.5	2
97	Fibrin(ogen) Peptides in Early Breast Cancer. Thrombosis and Haemostasis, 1989, 62, 819.	1.8	2
98	Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and Siset. Blood Transfusion, 2020, 18, 478-485.	0.3	2
99	Acute Erythroblastic Leukemia Terminating a Very Long-Lasting (27 Years) Hodgkin's Disease. Acta Haematologica, 1982, 67, 287-288.	0.7	1
100	Evidence for a Relationship between High Fibrinogen Levels and Decreased Thrombin Activity in vivo in Elderly Subjects. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1989, 19, 91-93.	0.5	1
101	t-PA Activity elicited by venous occlusion or DDAVP infusion does not produce plasmin activity in normal subjects. Thrombosis Research, 1990, 59, 1007-1011.	0.8	1
102	A routine silica-based activated partial thromboplastin time (Hemosil aPTT ^{SP}) mostly excludes the presence of lupus anticoagulant. International Journal of Laboratory Hematology, 2011, 33, e12-3.	0.7	1
103	Management of special conditions in patients on vitamin K antagonists. Internal and Emergency Medicine, 2012, 7, 407-413.	1.0	1
104	Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a reply to a rebuttal. Journal of Thrombosis and Haemostasis, 2013, 11, 1205-1206.	1.9	1
105	Comparison of prothrombin time INR and clot waveform analysis performed with 129 mmol/L and 105 mmol/L citrate tubes. International Journal of Laboratory Hematology, 2018, 40, e15-e16.	0.7	1
106	A Sardinian Family with Factor XI Deficiency. Hamostaseologie, 2019, 39, 398-403.	0.9	1
107	Optimizing Tailored DIEP Flap Insetting in Unilateral Immediate Free Autologous Breast Reconstruction. Plastic and Reconstructive Surgery, 2020, 145, 443e-444e.	0.7	1
108	Sex-based difference in anticoagulated patients with mechanical prosthetic heart valves and long-term mortality risk. International Journal of Clinical Practice, 2021, 75, e14064.	0.8	1

#	ARTICLE	IF	CITATIONS
109	The First Use of Human-Derived ADM in Prepectoral Direct-to-Implant Breast Reconstruction after Skin-Reducing Mastectomy. <i>Aesthetic Plastic Surgery</i> , 2021, 45, 2048-2057.	0.5	1
110	Clot Characterization by Multidisciplinary Approach: Biochemical and Imaging Parameters in A Hypocoagulative Setting. A Pilot Study. <i>Journal of Public Health Research</i> , 2021, 10, jphr.2021.2358.	0.5	1
111	Clinical history and gastrointestinal bleeding in patients taking oral anticoagulants. <i>International Journal of Cardiology</i> , 2021, 339, 134-137.	0.8	1
112	Oral anticoagulant therapy: should doctors change the way they give patients explanations?. <i>Thrombosis and Haemostasis</i> , 2003, 90, 159-60.	1.8	1
113	FIBRINOPEPTIDE BB 15-42 AND FIBRINOPEPTIDE A IN ATHEROSCLEROTIC DISEASE. <i>Thrombosis and Haemostasis</i> , 1987, 58, 2035.	1.8	0
114	FIBRINOPEPTIDE B6 15-42 IN LIVER CIRRHOSIS: A SENSITIVE INDICATOR OF MILD FIBRINOLYSIS ACTIVATION. , 1987, 58, 0264.		0
115	Relationship between Elevated Fibrinopeptide A Levels and Alpha-2-Antiplasmin. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1987, 17, 301-304.	0.5	0
116	Fibrinopeptide A and β^2 15-42 in Liver Cirrhosis. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1988, 18, 126-128.	0.5	0
117	THE OLD MANUAL TILT TUBE THROMBOTEST: STILL USEFUL IN THE MANAGEMENT OF ORAL ANTICOAGULANTS?. <i>Thrombosis Research</i> , 1996, 84, 379-384.	0.8	0
118	A Rare Case of Mondor Syndrome after Breast Reduction Surgery. Insert it into the Consent Form. <i>Breast Journal</i> , 2016, 22, 249-251.	0.4	0
119	Points of Care Testing International Normalized Ratio. <i>Point of Care</i> , 2018, 17, 59-62.	0.5	0
120	Re. Re. Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment and review of the literature. <i>International Journal of Hematology</i> , 2018, 108, 456-457.	0.7	0
121	Underuse of anticoagulant therapy in hospitalized older patients: comment on the article of Wojszel et al.. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 136-137.	1.0	0
122	Invited Response One: Blood Supply and Rotation of the "Bifidus Pedicle". <i>Aesthetic Plastic Surgery</i> , 2021, 45, 1927-1928.	0.5	0
123	Invited Response on: "Submuscular Reconstruction After NAC Sparing Mastectomy: Direct to Implant Breast Reconstruction with Human ADM Versus Tissue Expander". <i>Aesthetic Plastic Surgery</i> , 2021, 45, 1372-1374.	0.5	0
124	Bleeding Time and Oral Anticoagulant Therapy. <i>Thrombosis and Haemostasis</i> , 1993, 69, 523-524.	1.8	0
125	Empathy and the Educational Approach to Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants. <i>American Journal of Therapeutics</i> , 2020, Publish Ahead of Print, e355-e357.	0.5	0
126	Over-anticoagulation by vitamin K antagonists and gender differences. <i>International Journal of Cardiology</i> , 2022, , .	0.8	0

#	ARTICLE	IF	CITATIONS
127	Chronic spontaneous urticaria: a low-grade disseminated intravascular coagulation only partially reversed by Omalizumab. <i>Clinical and Experimental Medicine</i> , 0, , .	1.9	0